Sugi Predict

Sugi Predict / Compounds / SCHEMBL741235

SCHEMBL741235

SCHEMBL741235

CCc1ccc(OC)c(S(=O)(=O)Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ALPL P05186 1/20 0.51
▸ TRPV4 Q9HBA0 1/20 0.49
▸ TP53 P04637 1/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ GLA P06280 1/20 0.45
▸ HTT P42858 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ TSHR P16473 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ TUBB1 Q9H4B7 1/20 0.41
▸ CA2 P00918 1/20 0.40
▸ PTGS2 P35354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25046085 0.86 TRPV4 (0.62) ALPLTRPV4TP53SMN1; SMN2HTT
SCHEMBL30184732 0.86 TRPV4 (0.62) ALPLTRPV4TP53SMN1; SMN2HTT
SCHEMBL21609096 0.85 TRPV4 (0.50) ALPLTRPV4HTTTSHRCA2
SCHEMBL10962659 0.84 SMN1; SMN2 (0.61) ALPLTP53SMN1; SMN2GLAHTT
SCHEMBL8180786 0.83 TRPV4 (0.46) TRPV4SMN1; SMN2GLAHTTL3MBTL1
SCHEMBL14097342 0.83 CDC25A (0.53) ALPLTP53SMN1; SMN2GLAHTT
SCHEMBL24692565 0.83 ALPL (0.51) ALPLTP53SMN1; SMN2GLAHTT
SCHEMBL10640275 0.83 PKM (0.55) ALPLCA2
SCHEMBL24503566 0.82 TRPV4 (0.45) TRPV4SMN1; SMN2
SCHEMBL9724436 0.81 CA5A (0.61) TRPV4NPSR1L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630529-B2 GCN2 modulator compounds Alesta Therapeutics BV (NL) 2026-05-19 — — US disclosed
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 — — US disclosed
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives PFIZER (US) 2026-03-05 — — US disclosed
EP-4299135-B1 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-08-06 — — EP disclosed
US-12371425-B2 Benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2025-07-29 — — US disclosed
US-12365655-B2 Compounds CTXT PTY LTD (AU) 2025-07-22 — — US disclosed
WO-2025136811-A1 CHEMICAL COMPOUNDS AND USES THEREOF IDEAYA BIOSCIENCES, INC. (US) 2025-06-26 — — WO disclosed
CN-112334466-B Compounds of formula (I) CTXT私人有限公司 2025-05-30 — — CN disclosed
US-20250122182-A1 MYST Inhibitors Isosterix, Inc. 2025-04-17 — — US disclosed
EP-3986890-B9 BENZISOXAZOLE SULFONAMIDE DERIVATIVES PFIZER (US) 2025-04-16 — — EP disclosed
US-20110275800-A1 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-10 — — US disclosed
EP-2276731-A1 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 Boehringer Ingelheim International GmbH (DE) 2011-01-26 — — EP disclosed
EP-2134714-A1 TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY Biovitrum AB (publ) (SE) 2009-12-23 — — EP disclosed
WO-2009126675-A1 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-15 — — WO disclosed
US-20080293694-A1 New compounds BIOVITRUM AB (PUBL.) (SE) 2008-11-27 — — US disclosed
WO-2008110598-A1 TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY BIOVITRUM AB (PUBL) (SE) 2008-09-18 — — WO disclosed
US-4766241-A LOWER ACUTE TOXICITY HOECHST AKTIENGESELLSCHAFT (DE) 1988-08-23 — — US disclosed
US-4607030-A ANTIEDEMICS, HYPOTENSIVES HOECHST AKTIENGESELLSCHAFT (DE) 1986-08-19 — — US disclosed
EP-0088346-B1 2-AMINOMETHYL-PHENOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HOECHST AKTIENGESELLSCHAFT (DE) 1985-06-05 — — EP disclosed
EP-0088346-A2 2-Aminomethyl-phenol derivatives, process for their preparation, their use and pharmaceutical compositions containing them HOECHST AKTIENGESELLSCHAFT (DE) 1983-09-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630529-B2 GCN2 modulator compounds NR3C1, GCN1, EIF2AK4 ALPL 4801/4885TRPV4 2630/4885TP53 4741/4885
US-12371425-B2 Benzisoxazole sulfonamide derivatives BRIX1, RB1, BCR ALPL 4318/4885TRPV4 2910/4885TP53 725/4885
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B ALPL 3469/4885TRPV4 1449/4885TP53 4584/4885
US-20080293694-A1 New compounds HTR6, HTR1A, HTR1B ALPL 4875/4885TRPV4 407/4885TP53 4735/4885
US-20250122182-A1 MYST Inhibitors MNAT1, SUGT1, ACAT2 ALPL 4462/4885TRPV4 4752/4885TP53 14/4885
US-20260062406-A1 Benzisoxazole Sulfonamide Derivatives KAT8, KAT5, KAT7 ALPL 1890/4885TRPV4 3638/4885TP53 1230/4885
US-12365655-B2 Compounds SLC10A1, ABCB11, PCSK9 ALPL 1524/4885TRPV4 909/4885TP53 3504/4885
US-20110275800-A1 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 CCR10, CCR1, CCR4 ALPL 4885/4885TRPV4 425/4885TP53 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.